Cassava Sciences Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.18. The key difference: T-Rex 2X Inverse MSTR Daily Target ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MSTZ | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $27.92 |
52-Week Low | $0.87 | $3.88 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
MSTZ trades at $11.27, up 4.16% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights ETF performance unrelated to MSTZ, with no direct company updates provided.
The outlook is cautious due to bearish technicals and lack of fundamental data. Risks include market volatility and unverified financial health. Investment opportunity hinges on future earnings clarity and positive analyst coverage, which are currently absent.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →